公开(公告)号：EP3310813A1

公开(公告)日：2018-04-25

申请号：EP16732342.7

申请日：2016-06-17

申请人： Novartis AG

发明人： ABRAMS, Tinya ,  COHEN, Steven ,  D'ALESSIO, Joseph Anthony ,  DAMIANO, Jason ,  DURR, Clemens ,  GEIERSTANGER, Bernhard Hubert ,  HU, Qi-Ying ,  HUBER, Thomas ,  IMASE, Hidetomo ,  JIN, Yunho ,  MENEZES, Daniel ,  MILLER, Kathy ,  MOHSENI, Morvarid ,  OU, Weijia ,  RENDAHL, Katherine ,  UNO, Tetsuo ,  WAN, Yongqin ,  WANG, Xing

IPC分类号： C07K16/28 ,  A61K31/00 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/28 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.